FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378806255> ?p ?o ?g. }

• W4378806255 endingPage "3504" @default.
• W4378806255 startingPage "3494" @default.
• W4378806255 abstract "PEGylated lipid nanoparticle-based Covid-19 vaccines, including Pfizer’s BNT162b2 and Moderna’s mRNA-1273, have been shown to stimulate variable anti-PEG antibody production in humans. Anti-PEG antibodies have the potential to accelerate the plasma clearance of PEGylated therapeutics, such as PEGylated liposomes and proteins, and compromise their therapeutic efficacy. However, it is not yet clear whether antibody titers produced by PEGylated Covid-19 vaccines significantly affect the clearance of PEGylated therapeutics. This study examined how anti-PEG IgM levels affect the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) and compared the immunogenicity of a lipid nanoparticle formulation of linear DNA (DNA-LNP) to standard PEG-HSPC liposomes. DNA-LNP was prepared using the same composition and approach as Pfizer’s BNT162b2, except linear double-stranded DNA was used as the genetic material. PEGylated HSPC-based liposomes were formulated using the lipid rehydration and extrusion method. Nanoparticles were dosed IM to rats at 0.005–0.5 mg lipid/kg body weight 1 week before evaluating the plasma pharmacokinetics of clinically relevant doses of PLD (1 mg/kg, IV) or PEGylated interferon α2a (Pegasys, 5 μg/kg, SC). Plasma PEG IgM was compared between pre- and 1-week post-dose blood samples. The results showed that anti-PEG IgM production increased with increasing PEG-HSPC liposome dose and that IgM significantly correlated with the plasma half-life, clearance, volume of distribution, and area under the curve of a subsequent dose of PLD. The plasma exposure of Pegasys was also significantly reduced after initial delivery of 0.005 mg/ml PEG-HSPC liposome. However, a single 0.05 mg/kg IM dose of DNA-LNP did not significantly elevate PEG IgM and did not alter the IV pharmacokinetics of PLD. These data showed that PEGylated Covid-19 vaccines are less immunogenic compared to standard PEGylated HSPC liposomes and that there is an antibody threshold for accelerating the clearance of PEGylated therapeutics." @default.
• W4378806255 created "2023-06-01" @default.
• W4378806255 creator A5055028859 @default.
• W4378806255 creator A5058666484 @default.
• W4378806255 creator A5076286176 @default.
• W4378806255 creator A5076565903 @default.
• W4378806255 date "2023-05-31" @default.
• W4378806255 modified "2023-09-30" @default.
• W4378806255 title "Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats" @default.
• W4378806255 cites W1587071366 @default.
• W4378806255 cites W1988422289 @default.
• W4378806255 cites W1996217277 @default.
• W4378806255 cites W1997925348 @default.
• W4378806255 cites W2001983171 @default.
• W4378806255 cites W2007403365 @default.
• W4378806255 cites W2011891975 @default.
• W4378806255 cites W2032505506 @default.
• W4378806255 cites W2044767504 @default.
• W4378806255 cites W2056609366 @default.
• W4378806255 cites W2056616704 @default.
• W4378806255 cites W2063871592 @default.
• W4378806255 cites W2074401275 @default.
• W4378806255 cites W2075563097 @default.
• W4378806255 cites W2082556053 @default.
• W4378806255 cites W2083843762 @default.
• W4378806255 cites W2086471490 @default.
• W4378806255 cites W2086856055 @default.
• W4378806255 cites W2087167636 @default.
• W4378806255 cites W2089258057 @default.
• W4378806255 cites W2102771576 @default.
• W4378806255 cites W2112482119 @default.
• W4378806255 cites W2122941511 @default.
• W4378806255 cites W2160762238 @default.
• W4378806255 cites W2395806397 @default.
• W4378806255 cites W2418321459 @default.
• W4378806255 cites W2472635460 @default.
• W4378806255 cites W2529868311 @default.
• W4378806255 cites W2737469317 @default.
• W4378806255 cites W2784187371 @default.
• W4378806255 cites W2793125806 @default.
• W4378806255 cites W2807009021 @default.
• W4378806255 cites W2888472260 @default.
• W4378806255 cites W2948701168 @default.
• W4378806255 cites W3033778371 @default.
• W4378806255 cites W3046633757 @default.
• W4378806255 cites W3148255637 @default.
• W4378806255 cites W3161903464 @default.
• W4378806255 cites W3181842121 @default.
• W4378806255 cites W3197016216 @default.
• W4378806255 cites W3198884354 @default.
• W4378806255 cites W3204277088 @default.
• W4378806255 cites W4200222518 @default.
• W4378806255 cites W4283641637 @default.
• W4378806255 cites W4293512386 @default.
• W4378806255 cites W4295942559 @default.
• W4378806255 cites W4315640782 @default.
• W4378806255 doi "https://doi.org/10.1021/acs.molpharmaceut.3c00104" @default.
• W4378806255 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37256791" @default.
• W4378806255 hasPublicationYear "2023" @default.
• W4378806255 type Work @default.
• W4378806255 citedByCount "2" @default.
• W4378806255 countsByYear W43788062552023 @default.
• W4378806255 crossrefType "journal-article" @default.
• W4378806255 hasAuthorship W4378806255A5055028859 @default.
• W4378806255 hasAuthorship W4378806255A5058666484 @default.
• W4378806255 hasAuthorship W4378806255A5076286176 @default.
• W4378806255 hasAuthorship W4378806255A5076565903 @default.
• W4378806255 hasBestOaLocation W43788062551 @default.
• W4378806255 hasConcept C10138342 @default.
• W4378806255 hasConcept C104317684 @default.
• W4378806255 hasConcept C112705442 @default.
• W4378806255 hasConcept C135763542 @default.
• W4378806255 hasConcept C150903083 @default.
• W4378806255 hasConcept C159654299 @default.
• W4378806255 hasConcept C162324750 @default.
• W4378806255 hasConcept C167508917 @default.
• W4378806255 hasConcept C185154212 @default.
• W4378806255 hasConcept C185592680 @default.
• W4378806255 hasConcept C203014093 @default.
• W4378806255 hasConcept C207001950 @default.
• W4378806255 hasConcept C2776461080 @default.
• W4378806255 hasConcept C2776964284 @default.
• W4378806255 hasConcept C2779149719 @default.
• W4378806255 hasConcept C2780040827 @default.
• W4378806255 hasConcept C2780801004 @default.
• W4378806255 hasConcept C2780868878 @default.
• W4378806255 hasConcept C54400483 @default.
• W4378806255 hasConcept C55493867 @default.
• W4378806255 hasConcept C71924100 @default.
• W4378806255 hasConcept C86803240 @default.
• W4378806255 hasConcept C98274493 @default.
• W4378806255 hasConceptScore W4378806255C10138342 @default.
• W4378806255 hasConceptScore W4378806255C104317684 @default.
• W4378806255 hasConceptScore W4378806255C112705442 @default.
• W4378806255 hasConceptScore W4378806255C135763542 @default.
• W4378806255 hasConceptScore W4378806255C150903083 @default.
• W4378806255 hasConceptScore W4378806255C159654299 @default.
• W4378806255 hasConceptScore W4378806255C162324750 @default.

• next